Stifel Financial Corp Grows Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Stifel Financial Corp grew its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 26.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 188,844 shares of the biotechnology company’s stock after acquiring an additional 39,564 shares during the period. Stifel Financial Corp’s holdings in REGENXBIO were worth $1,460,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Voss Capital LP bought a new stake in REGENXBIO during the 4th quarter worth approximately $2,573,000. Tower Research Capital LLC TRC increased its holdings in shares of REGENXBIO by 442.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,138 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 10,714 shares during the period. Dimensional Fund Advisors LP raised its position in shares of REGENXBIO by 1.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company’s stock worth $9,054,000 after buying an additional 21,234 shares in the last quarter. Jump Financial LLC boosted its stake in REGENXBIO by 144.9% during the fourth quarter. Jump Financial LLC now owns 192,708 shares of the biotechnology company’s stock valued at $1,490,000 after buying an additional 114,005 shares during the period. Finally, Walleye Capital LLC purchased a new position in REGENXBIO during the fourth quarter worth about $681,000. 88.08% of the stock is owned by institutional investors.

REGENXBIO Stock Down 8.6 %

RGNX opened at $7.24 on Thursday. REGENXBIO Inc. has a 52 week low of $5.04 and a 52 week high of $17.35. The stock has a market cap of $362.85 million, a PE ratio of -1.44 and a beta of 1.11. The business has a 50 day moving average of $7.26 and a 200-day moving average of $8.06.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.26. The business had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. Equities analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on RGNX shares. Chardan Capital reiterated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Thursday, March 20th. The Goldman Sachs Group decreased their price target on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, April 17th. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, March 7th. Leerink Partners set a $24.00 target price on REGENXBIO in a research note on Tuesday, March 18th. Finally, Raymond James began coverage on REGENXBIO in a research note on Friday, February 7th. They set an “outperform” rating and a $27.00 price target for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, REGENXBIO has an average rating of “Moderate Buy” and an average price target of $31.63.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.